Publisher
Springer Berlin Heidelberg
Reference273 articles.
1. Baehr M, Kolter T, Seipke G, Eckel J (1997) Growth promoting and metabolic activity of the human insulin analog [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259–265
2. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring H (1998) The long-acting human insulin analog HOE901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123–129
3. Bowsher RR, Lynch RA, Brown-Augsburger P, Santa PF, Legan WE, Woodworth JR, Chance RE (1999) Sensitive RIA for the specific determination of insulin lispro. Clin Chem. 45(1):104–110
4. EMEA (European Agency for the Evaluation of Medical Products) (2001) Points to consider document on the non-clinical assessment of the carcinogenic potential of insulin analogs. European Agency for the Evaluation of Medicinal Products, London
5. Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH, Duckworth WC (1999) Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Metabolism 48(5):611–617